Sinusoidal Obstruction Syndrome
Conditions
Brief summary
The goal of this is to learn more about stem cell transplant and complications that some people have after their transplants, in particular sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease of the liver.
Detailed description
This is a multicenter, prospective, observational trial. We will measure biomarkers and determine thresholds that will predict increased risk for SOS in pediatric patients receiving HCT or high intensity chemotherapy/irradiation with the future goal of a randomized, interventional, open-label, multicenter trial that will test the preemptive use of defibrotide for prevention of SOS in an enriched high-risk population.
Interventions
OTHERSerial Blood Draws
Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
Sponsors
Indiana University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 25 Years
Healthy volunteers
No
Inclusion criteria
Age ≤ 25 years undergoing HCT for any reason who fulfill any ONE (1) of the following criteria: 1. History of hepatic disease as defined by: 1. Viral hepatitis (i.e., hepatitis C virus \[HCV\]) 2. Liver tumor before HCT 3. Hepatic fibrosis or cirrhosis before HCT as proven by liver biopsy 4. High aspartate aminotransferase (AST) (\> 2x ULN) before HCT (pre-transplant evaluation) 5. High alanine transaminase (ALT) (\> 2x ULN) before HCT 6. High bilirubin (\> 1.2x ULN) before HCT 2. HCT high-risk features including: a. Conditioning with high-risk modalities including: i. Busulfan (BU)-containing regimen particularly with oral BU + cyclophosphamide ii. TBI-containing regimen, particularly cyclophosphamide + total-body irradiation (TBI) b. ≥ 2 HCT c. Allo-HCT for leukemia \> or = second relapse d. Unrelated donor (URD) HCT e. Human leukocyte antigen (HLA) mismatch HCT (less than 10 of 10 for bone marrow/peripheral blood stem cell \[BM/PBSC\] or anything less than 6 of 6 for UCB) f. Use of sirolimus + tacrolimus prophylaxis for GVHD 3. High-risk disease states including: 1. Juvenile myelo-monocytic chronic leukemia (JMML) 2. Primary hemophagocytic lymphohistiocytosis (HLH) 3. Adrenoleukodystrophy 4. Osteopetrosis 4. Other high-risk features including: 1. Prior treatment with gemtuzumab ozogamicin 2. Use of hepatotoxic drugs 1 month before HCT and during HCT 3. Iron overload (i.e., thalassemia/sickle cell) with serum ferritin \> 1000ng/ml 4. Deficit of ATIII, T-PA (i.e., \< 30% normal values), and resistance to activated protein C if clinical indication (these values do not have to be specifically checked if no clinical history) 5. Young age \< 2 years but more than 1 month
Exclusion criteria
Patients who are transplanted but do not fulfill any of the above mentioned criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SOS proteomic markers | Until the end of the study evaluation, day 180 | Measure for 3 SOS proteomic markers, L-Ficolin, HA, and ST2, as early predictors of SOS incidence through study completion. |
Countries
United States
Outcome results
None listed